We have previously reported success with [177Lu]Lu-anti-PD-1 (177Lu-αPD-1) radioimmunotherapy (RIT) as a standalone treatment in experimental autoimmune encephalomyelitis (EAE), which is the most common preclinical model of MS. Here, PDCD1 is linked to experimental autoimmune encephalomyelitis.